Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 592

1.

The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.

Hemmerlein B, Johanns U, Halbfass J, Böttcher T, Heuser M, Radzun HJ, Thelen P.

Int J Oncol. 2004 May;24(5):1069-76.

PMID:
15067327
2.

mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas.

Hagemann T, Gunawan B, Schulz M, Füzesi L, Binder C.

Eur J Cancer. 2001 Oct;37(15):1839-46.

PMID:
11576837
3.

[Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].

Wei QY, Wu YQ, Fan SQ.

Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):212-6. Chinese.

PMID:
14653069
4.

In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.

Bhuvarahamurthy V, Kristiansen GO, Johannsen M, Loening SA, Schnorr D, Jung K, Staack A.

Oncol Rep. 2006 May;15(5):1379-84.

PMID:
16596214
5.

Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential.

Miyake H, Hara I, Gohji K, Yamanaka K, Hara S, Arakawa S, Nakajima M, Kamidono S.

Clin Cancer Res. 1999 Oct;5(10):2824-9.

6.
7.

Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.

Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC.

BMC Cancer. 2009 Jan 14;9:20. doi: 10.1186/1471-2407-9-20.

9.

Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma.

Christopoulos TA, Papageorgakopoulou N, Ravazoula P, Mastronikolis NS, Papadas TA, Theocharis DA, Vynios DH.

Oncol Rep. 2007 Oct;18(4):855-60.

PMID:
17786346
10.

Modifications of the radiosensitivity of a renal cancer cell line as a consequence of stable TIMP-1 overexpression.

Smyth A, Reid HM, Baker AH, McGlynn H.

Int J Radiat Biol. 2007 Jan;83(1):13-25.

PMID:
17357436
11.

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma.

Qiao ZK, Li YL, Lu HT, Wang KL, Xu WH.

World J Surg Oncol. 2013 Jan 3;11:1. doi: 10.1186/1477-7819-11-1.

12.

Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells.

Ho FM, Liu SH, Lin WW, Liau CS.

J Cell Biochem. 2007 May 15;101(2):442-50.

PMID:
17203468
13.

Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM.

Eur J Cancer. 2001 Nov;37(16):2040-9.

PMID:
11597382
14.
15.
16.
17.

[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].

Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.

Ai Zheng. 2004 Oct;23(10):1194-8. Chinese.

PMID:
15473934
18.
19.
20.

Regulation of mRNAs encoding MMP-9 and MMP-2, and their inhibitors TIMP-1 and TIMP-2 by androgens in the rat ventral prostate.

Limaye AM, Desai KV, Chavalmane AK, Kondaiah P.

Mol Cell Endocrinol. 2008 Nov 6;294(1-2):10-8. doi: 10.1016/j.mce.2008.07.003. Epub 2008 Jul 15.

PMID:
18675881

Supplemental Content

Support Center